000 04080nam a22004815i 4500
001 978-1-4614-1144-4
003 DE-He213
005 20140220083241.0
007 cr nn 008mamaa
008 111202s2012 xxu| s |||| 0|eng d
020 _a9781461411444
_9978-1-4614-1144-4
024 7 _a10.1007/978-1-4614-1144-4
_2doi
050 4 _aRS380
050 4 _aRS190-210
072 7 _aTDCW
_2bicssc
072 7 _aMED072000
_2bisacsh
082 0 4 _a615.19
_223
100 1 _aWilliams III, Robert O.
_eeditor.
245 1 0 _aFormulating Poorly Water Soluble Drugs
_h[electronic resource] /
_cedited by Robert O. Williams III, Alan B. Watts, Dave A. Miller.
250 _a1.
264 1 _aNew York, NY :
_bSpringer New York,
_c2012.
300 _aXII, 646p. 188 illus., 135 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aAAPS Advances in the Pharmaceutical Sciences Series,
_x2210-7371 ;
_v3
505 0 _aRoute-Specific Challenges in Delivery of Poorly Water Soluble Drugs -- Optimizing the Formulation of Poorly Water Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle Size Reduction Techniques -- Solubilized Formulations -- Injectable Formulations of Poorly Water Soluble Drugs -- Design and Development of Self-Emulsifying Lipid Formulations for Improving Oral Bioavailability of Poorly Water-Soluble and Lipophilic Drugs -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water Soluble Drugs -- Regulatory Considerations for Development and Commercialization of Poorly Water Soluble Drugs.
520 _aA pharmaceutical scientist’s approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound’s physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at minimum a working knowledge of each of the abovementioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop. There are numerous literature resources available to pharmaceutical scientists to educate and provide guidance toward formulations development with poorly water-soluble drugs; however, a single, comprehensive reference is lacking. Furthermore, without access to a vast journal library, the detailed methods used to implement these approaches are not available. The objective of this volume is therefore to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules.
650 0 _aMedicine.
650 0 _aPharmaceutical technology.
650 1 4 _aBiomedicine.
650 2 4 _aPharmaceutical Sciences/Technology.
700 1 _aWatts, Alan B.
_eeditor.
700 1 _aMiller, Dave A.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781461411437
830 0 _aAAPS Advances in the Pharmaceutical Sciences Series,
_x2210-7371 ;
_v3
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4614-1144-4
912 _aZDB-2-SBL
999 _c100999
_d100999